ZA200809528B - Treatment for depressive disorders - Google Patents

Treatment for depressive disorders

Info

Publication number
ZA200809528B
ZA200809528B ZA200809528A ZA200809528A ZA200809528B ZA 200809528 B ZA200809528 B ZA 200809528B ZA 200809528 A ZA200809528 A ZA 200809528A ZA 200809528 A ZA200809528 A ZA 200809528A ZA 200809528 B ZA200809528 B ZA 200809528B
Authority
ZA
South Africa
Prior art keywords
treatment
depressive disorders
depressive
disorders
Prior art date
Application number
ZA200809528A
Other languages
English (en)
Inventor
Curt D Wolfgang
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of ZA200809528B publication Critical patent/ZA200809528B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200809528A 2006-05-22 2008-11-07 Treatment for depressive disorders ZA200809528B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74786106P 2006-05-22 2006-05-22

Publications (1)

Publication Number Publication Date
ZA200809528B true ZA200809528B (en) 2009-11-25

Family

ID=38723631

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809528A ZA200809528B (en) 2006-05-22 2008-11-07 Treatment for depressive disorders

Country Status (11)

Country Link
US (1) US20090306137A1 (OSRAM)
EP (1) EP2029136A4 (OSRAM)
JP (1) JP2009538331A (OSRAM)
KR (1) KR20090029200A (OSRAM)
AU (1) AU2007253684A1 (OSRAM)
BR (1) BRPI0711872A2 (OSRAM)
CA (1) CA2652416A1 (OSRAM)
MX (1) MX2008014843A (OSRAM)
RU (1) RU2008150624A (OSRAM)
WO (1) WO2007137227A1 (OSRAM)
ZA (1) ZA200809528B (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
AU2011274787B2 (en) 2010-07-07 2016-06-16 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2665465A1 (en) * 2011-01-17 2013-11-27 Takeda Pharmaceutical Company Limited Orally dispersible tablet
US8426461B2 (en) 2011-01-17 2013-04-23 Takeda Pharmaceutical Company Limited Orally dispersible tablet
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
RU2465895C1 (ru) * 2011-09-08 2012-11-10 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения депрессивного невроза
JP6061924B2 (ja) * 2011-10-14 2017-01-18 武田薬品工業株式会社 口腔内分散性製剤
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
CA2865845C (en) 2012-03-14 2020-02-18 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
JP2015516979A (ja) * 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
JP5959083B2 (ja) 2012-05-18 2016-08-02 ヴァンダ ファーマシューティカルズ インコーポレイテッド （１Ｒ−ｔｒａｎｓ）−Ｎ−［［２−（２，３−ジヒドロ−４−ベンゾフラニル）シクロプロピル］メチル］プロパンアミドの代謝物
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
JP6406713B2 (ja) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
KR101484405B1 (ko) * 2013-08-14 2015-01-19 서울대학교산학협력단 Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
JP6585625B2 (ja) 2014-01-21 2019-10-02 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
RU2571546C1 (ru) * 2014-07-14 2015-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ дифференцированной диагностики и терапии синдрома ночной еды
EP3179993B1 (en) 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine for use in a method for the treatment of depression
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
MA54395A (fr) 2018-12-07 2022-03-16 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CN114502162B (zh) 2019-09-27 2025-03-28 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法
KR102287477B1 (ko) 2019-11-27 2021-08-09 (주)뉴로라이브 우울증 치료를 위한 사이클로세린 및 리튬 병용 요법
CN115380028A (zh) * 2020-02-04 2022-11-22 明德赛特制药公司 用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
AU2927392A (en) 1991-11-01 1993-06-07 National-Standard Company Age resistant solder coatings
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
ES2398434T3 (es) 2001-08-31 2013-03-19 Novartis Ag Isómeros ópticos de un metabolito de iloperidona
ES2358416T3 (es) 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
ATE503845T1 (de) 2001-12-10 2011-04-15 Novartis Pharma Gmbh Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone

Also Published As

Publication number Publication date
WO2007137227A1 (en) 2007-11-29
KR20090029200A (ko) 2009-03-20
AU2007253684A1 (en) 2007-11-29
MX2008014843A (es) 2008-12-05
US20090306137A1 (en) 2009-12-10
EP2029136A1 (en) 2009-03-04
EP2029136A4 (en) 2010-01-06
RU2008150624A (ru) 2010-06-27
JP2009538331A (ja) 2009-11-05
CA2652416A1 (en) 2007-11-29
BRPI0711872A2 (pt) 2011-12-06

Similar Documents

Publication Publication Date Title
EP2029136A4 (en) TREATMENT FOR DEPRESSION DISEASES
ZA200809527B (en) Treatment for depressive disorders
IL197001A0 (en) Combination treatment for metabolic disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
GB0602178D0 (en) Therapeutic treatment
GB0606604D0 (en) Treatment apparatus
ZA200807015B (en) Dihydrothienopyrimidine for treating inflammatory disorders
EP2010187A4 (en) CONNECTIONS FOR DISEASES AND FUNCTIONAL DISORDERS
IL193747A0 (en) New therapeutic combinations for the treatment of depression
EP2337866A4 (en) MULTIDIMENSIONAL HUMAN BIOMARKER HYPERESPACE MAPPING FOR DEPRESSIVE DISORDERS
PL1993589T3 (pl) Sposoby leczenia chorób neurologicznych
EP2230910A4 (en) PRE-SURGICAL TREATMENT
GB0624874D0 (en) Treatment
GB0711342D0 (en) Well treatment
EP2106253A4 (en) TREATMENT OF ACOUPHEN
GB0600692D0 (en) Well treatment
GB0608655D0 (en) Therapeutic Treatment
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
GB0702537D0 (en) Treatment for excessive adiposity
GB0716784D0 (en) Well treatment
GB0610909D0 (en) Therapeutic treatment
IL207906A0 (en) Treatment for ocular-related disorders
GB0525540D0 (en) New treatment
GB0511769D0 (en) Treatment